Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 6
2010 4
2011 3
2016 1
2017 1
2018 1
2019 1
2020 1
2021 7
2022 11
2023 7
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Free PMC article. Clinical Trial.
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.
Solitano V, Facciorusso A, McGovern DPB, Nguyen T, Colman RJ, Zou L, Boland BS, Syversen SW, Jørgensen KK, Ma C, Armuzzi A, Wilson A, Jairath V, Singh S. Solitano V, et al. Among authors: syversen sw. Clin Gastroenterol Hepatol. 2023 Nov;21(12):3019-3029.e5. doi: 10.1016/j.cgh.2023.03.044. Epub 2023 Apr 13. Clin Gastroenterol Hepatol. 2023. PMID: 37061107 Review.
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW. Brun MK, et al. Among authors: syversen sw. J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26. J Intern Med. 2023. PMID: 36843323
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
Kared H, Jyssum I, Alirezaylavasani A, Egner IM, The Tran T, Tietze L, Lund KP, Tveter AT, Provan SA, Ørbo H, Haavardsholm EA, Vaage JT, Jørgensen K, Syversen SW, Lund-Johansen F, Goll GL, Munthe LA. Kared H, et al. Among authors: syversen sw. Front Immunol. 2024 Feb 22;15:1296273. doi: 10.3389/fimmu.2024.1296273. eCollection 2024. Front Immunol. 2024. PMID: 38455062 Free PMC article.
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW. Brun MK, et al. Among authors: syversen sw. J Intern Med. 2022 Sep;292(3):477-491. doi: 10.1111/joim.13495. Epub 2022 Apr 26. J Intern Med. 2022. PMID: 35411981 Free PMC article. Clinical Trial.
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, Böhm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compán V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD. Krieckaert CL, et al. Among authors: syversen sw. Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12. Ann Rheum Dis. 2023. PMID: 35551063
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW. Brun MK, et al. Among authors: syversen sw. Lancet Rheumatol. 2024 Apr;6(4):e226-e236. doi: 10.1016/S2665-9913(23)00341-7. Epub 2024 Feb 22. Lancet Rheumatol. 2024. PMID: 38402891 Clinical Trial.
47 results